（以下无正文） 基蛋生物科技股份有限公司独立董事关于 第三届董事会第二十四次会议 相关事项的事前认可意见 根据《中华人民共和国公司法》《中华人民共和国证券法》、中国证券监督管 理委员会《上市公司独立董事规则》《上市公司治理准则》及《公司章程》等有 关规定，经认真审阅公司第三届董事会第二十四次会议有关会议材料后，现就有 关事项发表如下事前认可意见： 一、《关于公司 2023 年半年度利润分配预案的议案》的事前认可意见 根据《公司法》《上市公司监管指引第 3 号——上市公司现金分红》及《公 司章程》的相关规定，我们认为公司 2023 年半年度利润分配预案综合考虑了公 司盈利能力、经营发展规划、股东回报等因素，能够保障股东的合理回报并兼顾 公司的可持续发展，符合公司及全体股东特别是中小股东的利益。我们同意将利 润分配预案提交公司董事会审议。 （以下无正文，为《基蛋生物科技股份有限公司独立董事关于第三届董事会第二 十四次会议相关事项的事前认可意见》之签署页） 独立董事（签名）： 万遂人： 俞红海： 骆 竞： ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-024 基蛋生物科技股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2023 年 9 月 13 日 14 点 00 分 召开地点：南京市六合区沿江工业开发区博富路 9 号基蛋生物科技股份有限 公司四楼会议室 股东大会召开日期：2023年9月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第一次临时股东大会 (二) 股东大会召集人：董事会 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 13 日 至 2023 年 9 月 13 日 采用上海证券交易所网络投票系统，通过交 ...

公司 2023 年半年度利润分配预案综合考虑了行业特点、公司发展阶段等因 素，符合公司的实际发展及运营情况，能够保障股东的合理回报并兼顾公司的可 持续发展，该议案已经通过了董事会审议表决，审议和表决程序符合法律法规和 《公司章程》的规定。我们一致同意该议案，并提请公司股东大会审议。 （以下无正文） 基蛋生物科技股份有限公司独立董事 关于第三届董事会第二十四次会议相关事项的 独立意见 按照法律法规、《公司章程》及《上市公司独立董事规则》的要求，我们作 为基蛋生物科技股份有限公司（以下简称"公司"）的独立董事，本着实事求是、 认真负责的态度，对第三届董事会第二十四次会议相关事项进行了审查，发表意 见如下： 一、《关于公司拟开展外汇套期保值业务的议案》的独立意见 我们认真审阅了《关于公司拟开展外汇套期保值业务的议案》相关文件，基 于自身的独立判断，现发表独立意见如下：公司以规避和防范汇率波动风险为目 的所开展的外汇套期保值业务与日常经营紧密相关，公司开展外汇套期保值业务 可以进一步提升外汇风险管理能力，减少汇率波动对经营业绩的影响。公司制定 的可行性分析报告符合有关法律、法规的规定，并已建立健全相应的风险管理体 系 ...

一、对外投资概述 证券代码：603387 证券简称：基蛋生物 公告编号：2023-023 基蛋生物科技股份有限公司 关于投资建设研发及办公综合大楼的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资项目名称：研发及办公综合大楼 投资金额：预计总投资 4 亿元人民币，包含土地价款、建筑主体工程及 配套设施工程费用。项目最终投资总额以实际投资金额为准。 相关风险提示：在项目建设过程中，可能存在相关政策、宏观经济等方 面的不确定性风险，有可能会影响项目的正常实施。公司将根据实际情况，依法 合规推行项目进展，规避项目风险。 为满足公司未来发展规划对经营场所的需求，优化资源配置，为公司的可持 续长远发展提供有力的硬件保障，公司投资建设研发及办公综合大楼。该项目占 地面积约 36,976 平方米，总建筑面积约 95,912 平方米，其中地上建筑面积约 73,794 平方米，地下建筑面积约 22,118 平方米，主要建筑内容为集研发、办公 等功能于一体的综合大楼及其他相关配套设施。公司已取得项目所需建设用地以 及《投 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-027 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 09 月 12 日上午 10:00-11:00 基蛋生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于2023年09月05日(星期二)至09月11日(星期一)16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱IR@getein.cn进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 基蛋生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 29 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上 半年度经营成果、财务状况，公司计划于 2 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-026 一、监事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第三届监事会第十一次会 议的通知已于2023年8月18日以电子邮件的方式发出，通知了全体监事和其他列 席人员。公司本次监事会会议于2023年8月28日以通讯表决方式召开。会议应到 监事人3人，实到监事3人；公司董事会秘书和财务负责人列席了本次监事会会议。 会议由监事会主席李靖召集和主持。本次会议召集、召开符合《中华人民共 和国公司法》及有关法律、法规和《公司章程》的规定。 二、监事会会议审议情况 （一）审议并通过《关于<公司2023年半年度报告>及其摘要的议案》 基蛋生物科技股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司全体监事出席本次会议 是否有监事投反对或弃权票：否 本次监事会议案全部获得通过 监事会核查本项议案后认为：《公司2023年半年度报告》的编制和审议程序 符合法律、法规、《公司章程》和公司内部管理制度的 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2023-022 基蛋生物科技股份有限公司 关于 2023 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：向全体股东每10股派发人民币1元（含税）。 本次利润分配以实施权益分派股权登记日总股本数为基数，具体日期将 在权益分派实施公告中明确,在实施权益分派的股权登记日前公司总股本发生变 动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整情 况。 一、利润分配方案内容 基蛋生物科技股份有限公司（合并报表） 2023年1-6月实现净利润 171,580,000.10元，其中归属上市公司股东的净利润168,720,454.45元。2023年 半年度公司（合并报表）可供分配利润1,471,522,388.59元，母公司可供分配利 润1,249,703,008.38元（数据未经审计）。 基于对公司未来发展的良好预期，综合考虑公司经营现状、资产规模及盈余 情况，在保证公司正常经营和长远发展的前提下，为回报全 ...

Financial Performance - In 2022, the company achieved a net profit of RMB 503,944,698.54, with a net profit attributable to shareholders of RMB 498,909,980.40[6]. - The company proposed a cash dividend of RMB 3 per 10 shares, amounting to a total cash dividend of RMB 152,146,055.10, which represents 30.50% of the net profit attributable to shareholders[7]. - The total distributable profit for 2022 was RMB 1,454,947,989.25, after accounting for the profit distribution and retained earnings[6]. - The parent company reported a net profit of RMB 433,531,627.04 for 2022, with a total distributable profit of RMB 1,228,815,194.65[6]. - The company's operating revenue for 2022 reached ¥1,821,860,703.15, representing a year-on-year increase of 29.97%[25]. - The net profit attributable to shareholders for 2022 was ¥498,909,980.40, up 25.04% compared to the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 25.59% to ¥461,538,014.58[25]. - Basic earnings per share for 2022 were ¥0.98, an increase of 24.05% from ¥0.79 in 2021[26]. - The weighted average return on equity for 2022 was 21.76%, up from 20.43% in 2021[26]. - Total assets at the end of 2022 amounted to ¥3,677,437,948.24, reflecting a year-on-year growth of 17.19%[25]. Risk Management and Compliance - The company has outlined various risk factors that may affect its future development strategies and operational goals[10]. - The company has no non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[10]. - The board of directors has ensured the authenticity, accuracy, and completeness of the annual report[4]. - The company received a standard unqualified audit report from Zhongtian Yun Accounting Firm[5]. Research and Development - The company achieved a research and development investment of 26,205.90 million yuan, a year-on-year increase of 40.19%, accounting for 14.38% of operating revenue[49]. - The number of R&D personnel increased to 632, up by 184 from the beginning of 2022[49]. - The company has 500 valid patents as of December 31, 2022, with 310 authorized patents, including 30 invention patents[49]. - The company has developed eight major technology platforms, including POCT, chemiluminescence, biochemical testing, and molecular diagnostics, enhancing its product system from single POCT products to a diverse range[70]. - The company is committed to continuous innovation in product development, focusing on unmet clinical needs[50]. Product Development and Market Expansion - The company launched several new products, including the MAGICL6200 fully automated chemiluminescence analyzer (400T/H) and the CM1000 fully automated biochemical analyzer (1000T/H)[50]. - The company launched the Metis600 emergency blood cell line, which integrates multiple testing capabilities for clinical needs, including blood routine, inflammation, cardiovascular, and glycation tests[40]. - The company is focusing on expanding its market share in grade hospitals by increasing penetration in previously untapped departments[38]. - The company has expanded its chemiluminescence product line to 78 items, including 11 cardiovascular projects, maintaining a leading position in the market[44]. - The company aims to further develop its product offerings in areas such as coagulation series and liver cancer screening, enhancing its competitive edge in the chemiluminescence market[46]. Marketing and Sales Strategy - The company implemented a dual-driven marketing reform strategy focusing on "core" and "collaboration" to enhance growth[52]. - The company has established a comprehensive after-sales service system with over 200 frontline engineers and 30 technical engineers nationwide[59]. - The company is focusing on proactive maintenance and upgrades for large instruments to improve customer satisfaction[59]. - The company aims to leverage new policies to enhance the construction of county-level medical institutions, benefiting the IVD sector[66]. - The company is focusing on expanding its direct sales team to enhance customer loyalty and market barriers[81]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[153]. - The supervisory board has 3 members, including 1 employee representative, fulfilling its duties to oversee financial conditions and major matters[154]. - The company has established a robust information disclosure system, ensuring timely and accurate communication of significant information to shareholders[155]. - The company maintains independent operations with complete assets, personnel, and financial systems, ensuring no conflicts of interest with controlling shareholders[156]. - The company has conducted 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders and no rejected resolutions[159]. Employee and Management Practices - The company has established a comprehensive welfare system for employees, including various benefits to enhance employee satisfaction and belonging[184]. - The company conducted training programs focusing on R&D processes, safety production, and management talent development during the reporting period[185]. - The company’s remuneration policy aims to align employee development with corporate interests, ensuring fair and competitive compensation[184]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.0898 million yuan[170]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion RMB[167]. - The company plans to invest 200 million RMB in marketing to support the launch of new products and enhance brand visibility[167]. - The company aims to establish wholly-owned subsidiaries in Hong Kong, Singapore, and Germany, with plans to set up offices in Southeast Asia, South Asia, and Africa to deepen local market penetration[143]. - The company plans to increase R&D investment and strengthen technological innovation to enhance core competitiveness and improve operational performance[151].

Financial Performance - The company's operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.66% compared to the same period last year[2] - Net profit attributable to shareholders was ¥121,526,036.35, down 44.44% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥100,536,845.57, a decline of 54.32%[2] - Basic and diluted earnings per share were both ¥0.24, down 44.19% from the previous year[2] - Total operating revenue for Q1 2023 was ¥384,316,306.14, a decrease of 32.7% compared to ¥570,715,217.73 in Q1 2022[18] - Net profit for Q1 2023 was ¥124,371,119.11, a decline of 43.7% from ¥220,693,233.53 in Q1 2022[19] - The total comprehensive income for Q1 2023 was ¥124,267,374.11, down from ¥220,693,233.53 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was ¥13,484,563.45, representing a significant drop of 79.84%[2] - In Q1 2023, the cash inflow from operating activities was CNY 528,041,082.97, a decrease of 21.1% compared to CNY 669,337,060.24 in Q1 2022[22] - The net cash flow from operating activities was CNY 13,484,563.45, down 79.9% from CNY 66,898,060.91 in the same period last year[22] - Cash inflow from investment activities totaled CNY 186,730,257.77, significantly up from CNY 42,531,695.56 in Q1 2022[22] - The net cash flow from investment activities was CNY 103,596,691.92, compared to a negative CNY 15,619,831.84 in Q1 2022[22] - Cash inflow from financing activities was CNY 297,813,000.00, down from CNY 376,609,940.27 in the previous year[23] - The net cash flow from financing activities was negative CNY 26,790,759.52, a decline from positive CNY 51,380,646.72 in Q1 2022[23] - The ending balance of cash and cash equivalents was CNY 732,976,882.93, down from CNY 1,045,222,484.13 at the end of Q1 2022[23] - The company reported a cash increase of CNY 88,332,104.53 in Q1 2023, compared to CNY 100,071,255.50 in Q1 2022[23] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,671,973,340.42, a slight decrease of 0.15% from the end of the previous year[3] - The company's total liabilities as of Q1 2023 amounted to ¥892,257,607.28, a decrease from ¥1,012,840,595.85 in the previous period[17] - The total equity attributable to shareholders was ¥2,603,189,418.94, an increase from ¥2,482,468,375.18 year-over-year[17] - Shareholders' equity attributable to the parent company increased by 4.86% to ¥2,603,189,418.94 compared to the end of the previous year[3] Revenue Breakdown - The decline in revenue was primarily attributed to a decrease in COVID-related business compared to the previous year[6] - In Q1 2023, the company achieved a revenue of 23.52 million RMB from COVID-related business, a significant decline of 93.11% year-on-year[10] - Excluding COVID revenue, the company's self-produced products generated a total revenue of 286.28 million RMB, marking a year-on-year increase of 71.69%[10] - The POCT product line reported a revenue of 213.16 million RMB, reflecting a year-on-year growth of 56.21%[11] - The sales revenue from the chemical luminescence product line reached 43.18 million RMB, showing a substantial increase of 277.64% year-on-year[11] Research and Development - The company continues to focus on R&D, aiming to enhance competitiveness across its IVD product lines[12] - Research and development expenses for Q1 2023 were ¥55,164,547.70, up from ¥50,924,275.03 in Q1 2022, indicating a focus on innovation[18] - The company plans to accelerate the market validation and coverage of the newly launched Metis6000 fully automated immunoassay line[11] Shareholder Information - The company had a total of 38,070 common shareholders at the end of the reporting period[8]

证券代码：603387 证券简称：基蛋生物 公告编号：2023-012 基蛋生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 18 日上午 09:00-10:00 会议召开时间：2023年05月18日(星期四)上午09:00-10:00 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 投资者可于2023年05月11日(星期四)至05月17日(星期三)16:00前登录 上证路演中心网站首页点击"提问预 ...